Shattuck Labs, Inc. (STTK)
NASDAQ: STTK · Real-Time Price · USD
1.160
-0.090 (-7.20%)
At close: Nov 4, 2024, 4:00 PM
1.190
+0.030 (2.59%)
After-hours: Nov 4, 2024, 6:19 PM EST

Company Description

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States.

The company’s lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.

Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

Shattuck Labs, Inc.
Shattuck Labs logo
Country United States
Founded 2016
IPO Date Oct 9, 2020
Industry Biotechnology
Sector Healthcare
Employees 75
CEO Taylor Schreiber

Contact Details

Address:
500 West 5th Street, Suite 1200
Austin, Texas 78701
United States
Phone 512 900 4690
Website shattucklabs.com

Stock Details

Ticker Symbol STTK
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $17.00
CIK Code 0001680367
CUSIP Number 82024L103
ISIN Number US82024L1035
Employer ID 81-2575858
SIC Code 2834

Key Executives

Name Position
Dr. Taylor H. Schreiber M.D., Ph.D. Co-Founder, Chief Executive Officer and Director
Andrew R. Neill M.B.A. Chief Financial Officer
Dr. Arunthathy Nirmalini Pandite M.B.A., M.D. Chief Medical Officer
Dr. Abhinav A. Shukla Ph.D. Chief Technical Officer
Conor Richardson CPA Vice President of Investor Relations
Dr. Stephen Stout J.D., Ph.D. General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
Casi DeYoung Chief Business Officer
Dr. Thomas Lampkin Pharm.D. Senior Vice President of Regulatory Affairs
George Fromm Ph.D. Co-Chief Scientific Officer
Suresh de Silva Ph.D. Co-Chief Scientific Officer

Latest SEC Filings

Date Type Title
Nov 4, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 24, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Oct 1, 2024 8-K Current Report
Aug 16, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Aug 1, 2024 10-Q Quarterly Report
Aug 1, 2024 8-K Current Report
Jun 14, 2024 8-K Current Report
Jun 11, 2024 8-K/A [Amend] Current report
Jun 10, 2024 8-K Current Report
May 2, 2024 10-Q Quarterly Report